<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955773</url>
  </required_header>
  <id_info>
    <org_study_id>112110</org_study_id>
    <nct_id>NCT00955773</nct_id>
  </id_info>
  <brief_title>A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects</brief_title>
  <acronym>Cancer</acronym>
  <official_title>An Open-Label, Dose-Escalation, Phase IB II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With Oral Everolimus in Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the recommended dose and regimen for the orally
      administered MEK inhibitor GSK1120212 dosed in combination with everolimus in subjects with
      solid tumors. The escalation part of the study will determine the MTD. The combination will
      be further explored in the expansion part in subjects with metastatic pancreatic cancer. In
      addition, subjects with KRAS mutant non-small cell lung cancer will be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MEK112110 is a dose-escalation, open-label study to determine the recommended dose and
      regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with
      everolimus in subjects with solid tumors. This will be accomplished using a dose-escalation
      procedure starting at low doses of GSK1120212 and everolimus. Dose escalation will continue
      based on predefined parameters until the maximum tolerated dose is identified. The
      recommended doses and regimens will be selected based on the safety and pharmacokinetic
      profiles. The clinical activity of GSK1120212 dosed in combination with everolimus will be
      explored further in an expansion cohort consisting of 20 subjects with metastatic pancreatic
      cancer. In addition a substudy will be conducted in 40 subjects with KRAS-mutant non-small
      cell lung cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2009</start_date>
  <completion_date type="Actual">November 8, 2011</completion_date>
  <primary_completion_date type="Actual">November 8, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs and changes in laboratory values and vital signs</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate, CR + PR of GSK1120212 and everolimus in KRAS-mutant NSCLC.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GSK1120212 and everolimus PK parameters following repeat-dose (Day 15) administration of GSK1120212 and everolimus, including AUC(0-tau), Ct, Cmax, tmax, and t1/2, data permitting</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response as defined by RECIST 1.1.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA 19-9 levels compared to radiological response, per RECIST 1.1, over time for each pancreatic cancer subject</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population PK parameters, oral clearance and oral volume of distribution of GSK1120212 and everolimus will be determined. Dependant upon the final compartmental model describing GSK1120212 + everolimus, add. PK may also be estimated.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit response rate CR+PR+SD greater than 4mos</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 to 30 solid tumor subjects will be dosed with GSK1120212 in combination with everolimus to identify Maximum Tolerated Dose. Subjects will continue on study drug until disease progression or withdraw consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 subjects with pancreatic cancer will receive the recommended dose identified in group I. Subjects will remain on study drug until disease progression or withdrawal from consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 40 lung cancer subjects will receive the recommended dose identified in group I. Subjects will remain on study until disease progression or withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1120212 plus everolimus</intervention_name>
    <description>Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.</description>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  Age 18 years old or older and able to swallow oral medication.

          -  Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology
             (ECOG) scale for Dose Escalation Cohort. Subjects with ECOG of 2 can be enrolled for
             expansion cohort.

          -  Tumor Type criteria as listed in the protocol

          -  Fasting glucose &lt; 126mg/dL

          -  Male subjects must agree to use one of the contraception methods listed in the
             protocol.

          -  A female subject is eligible to participate if she is of non-childbearing potential,
             and if she is of childbearing potential she must use protocol defined contraception
             methods.

          -  Calcium phosphate product less than or equal to 4.0 mmol2/L2 (50 mg2/dL2)

          -  Adequate organ system function as defined below in the protocol.

        Exclusion Criteria:

          -  Malignancies related to HIV or solid organ transplant.

          -  Primary malignant brain tumors.

          -  Chemotherapy, radiotherapy, or immunotherapy within 28 days (or 42 days for prior
             nitrosoureas or mitomycin C) prior to the first dose of GSK1120212. Chemotherapy
             regimens given continuously or on a weekly basis with limited potential for delayed
             toxicity are permitted with approval of a GSK Medical Monitor if dosing of that agent
             is terminated at least 14 days prior to the first dose of GSK1120212.

          -  Use of an investigational anti-cancer drug within 28 days or 5 half-lives, whichever
             is shorter preceding the first dose of GSK1120212 - as long as a minimum of 14 days
             has passed between the last dose of the prior investigational anti-cancer drug and the
             first dose of GSK1120212.

          -  Previous treatment with an mTOR inhibitor unless approved by GSK Medical Monitor.

          -  Previous treatment with GSK1120212.

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator or GSK
             Medical Monitor, contraindicates their participation.

          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to the study drug, DMSO, or excipients. (To date there are no known
             FDA approved drugs chemically related to GSK1120212).

          -  Use of a prohibited medication (as defined in the protocol).

          -  Current use of anticoagulants (e.g. warfarin, heparin) at therapeutic levels within
             seven days prior to the first dose of GSK1120212. Low dose (prophylactic) low
             molecular weight heparin (LMWH) is permitted provided that subject's PT and PTT meet
             entry criteria. Subjects required therapeutic levels of LMWH must receive approval
             from GSK Medical Monitor and monitored appropriately as clinically indicated.

          -  Gastrointestinal disease predicted to interfere with absorption of an oral drug,
             systemic disease, major surgery, or social/psychological issues that in the opinion of
             investigators would jeopardize compliance with protocol.

          -  History of retinal vein occlusion (RVO) or central serous retinopathy (CSR).

          -  Predisposing factors to RVO including uncontrolled hypertension, uncontrolled
             diabetes, uncontrolled hyperlipidemia, and coagulopathy.

          -  Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk
             factor for RVO or CSR.

          -  Intraocular pressure &gt; 21mm Hg as measured by tonography.

          -  Glaucoma diagnosed within 1 month prior to study Day 1.

          -  Symptomatic or untreated leptomeningeal or brain metastases or spinal cord
             compression. Subjects previously treated for these conditions that are asymptomatic
             and off corticosteroids for at least two weeks are permitted. Subjects are not
             permitted to receive enzyme inducing anti-epileptic drugs (EIAEDs).

          -  Unresolved toxicity greater than common terminology criteria for adverse events
             (CTCAE) grade 1 from previous anti-cancer therapy except alopecia (if applicable)
             unless agreed to by a GSK Medical Monitor and the Investigator.

          -  History of acute coronary syndromes (including unstable angina), coronary angioplasty,
             or stenting within the past 24 weeks.

          -  QTc interval â‰¥ 480 msecs.

          -  Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA)
             functional classification system.

          -  Pregnant or lactating female.

          -  History or active hepatitis B or C.

          -  History of HIV infection.

          -  Subjects on chronic antifungal therapy.

          -  Unwillingness or inability to follow the procedures outlined in the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 20</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/112110?search=study&amp;search_terms=112110#rs</url>
    <description>Results for study 112110 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2009</study_first_submitted>
  <study_first_submitted_qc>August 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2009</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK1120212, everolimus, solid tumors, pancreatic cancer, non-small lung cancer, KRAS-mutant</keyword>
  <keyword>cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

